S Squared Technology LLC Makes New Investment in Krystal Biotech, Inc. $KRYS

Posted by Brenda Bartman on Aug 25th, 2026

S Squared Technology LLC purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 77,545 shares of the company’s stock, valued at approximately $28,821,150. Krystal Biotech accounts for approximately 0.0% of S Squared Technology LLC’s investment portfolio, making the stock its 2nd largest position. S Squared Technology LLC owned 0.26% of Krystal Biotech as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of KRYS. OMERS ADMINISTRATION Corp purchased a new position in shares of Krystal Biotech during the 2nd quarter worth $1,442,000. Sanctuary Advisors LLC bought a new position in Krystal Biotech during the 2nd quarter worth approximately $1,001,000. Biondo Investment Advisors LLC acquired a new position in shares of Krystal Biotech during the second quarter valued at approximately $26,368,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Krystal Biotech during the second quarter valued at $447,000. Finally, Quantbot Technologies LP acquired a new position in Krystal Biotech during the second quarter valued at approximately $113,000. Institutional investors own 86.29% of the company’s stock.

Insider Activity

In other news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 51,000 shares of company stock valued at $16,278,020. 13.10% of the stock is currently owned by company insiders.

Krystal Biotech Stock Down 1.9%

Shares of KRYS traded down $6.71 during mid-day trading on Friday, reaching $350.75. The company’s stock had a trading volume of 82,835 shares, compared to its average volume of 337,598. The business has a fifty day moving average of $348.57 and a 200 day moving average of $303.83. The company has a market cap of $10.38 billion, a price-to-earnings ratio of 43.95 and a beta of 0.53. Krystal Biotech, Inc. has a 1 year low of $136.73 and a 1 year high of $382.54.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, analysts predict that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Evercore reissued an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. TD Cowen lifted their price target on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. HC Wainwright boosted their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. Finally, Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.40.

Read Our Latest Stock Analysis on KRYS

About Krystal Biotech

(Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.